[{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Credit Pharmaceutical","sponsor":"Glogen Clinical Research Pvt. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Credit Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Credit Pharmaceutical \/ Glogen Clinical Research Pvt. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Credit Pharmaceutical \/ Glogen Clinical Research Pvt. Ltd"},{"orgOrder":0,"company":"Marinex International Sp. z o.o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"POLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Marinex International Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"Marinex International Sp. z o.o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Marinex International Sp. z o.o. \/ Undisclosed"},{"orgOrder":0,"company":"University of Reading","sponsor":"Biotechnology and Biological Sciences Research Council | Unilever | Foundation for Research Science and Technology (New Zealand)","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Reading \/ Biotechnology and Biological Sciences Research Council | Unilever | Foundation for Research Science and Technology (New Zealand)","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Biotechnology and Biological Sciences Research Council | Unilever | Foundation for Research Science and Technology (New Zealand)"},{"orgOrder":0,"company":"University of Stirling","sponsor":"Danone Nutricia Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Stirling","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Stirling \/ Danone Nutricia Research","highestDevelopmentStatusID":"1","companyTruncated":"University of Stirling \/ Danone Nutricia Research"},{"orgOrder":0,"company":"University Hospital Carl Gustav Carus","sponsor":"University of Giessen | Clinical Evaluation Research Unit at Kingston General Hospital | GWT-TUD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University Hospital Carl Gustav Carus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Carl Gustav Carus \/ University of Giessen | Clinical Evaluation Research Unit at Kingston General Hospital | GWT-TUD","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Carl Gustav Carus \/ University of Giessen | Clinical Evaluation Research Unit at Kingston General Hospital | GWT-TUD"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nordic Pharma \/ Nutrasource","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Pharma \/ Nutrasource"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"MetaProteomics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MetaProteomics LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MetaProteomics LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MetaProteomics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"VA Connecticut Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ VA Connecticut Healthcare System","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ VA Connecticut Healthcare System"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"True Eye Experts - New Tampa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Neurology","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa"},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"Sunnybrook Health Sciences Centre | Lotte & John Hecht Memorial Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"Canadian College of Naturopathic Medicine \/ Sunnybrook Health Sciences Centre | Lotte & John Hecht Memorial Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Canadian College of Naturopathic Medicine \/ Sunnybrook Health Sciences Centre | Lotte & John Hecht Memorial Foundation"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Hamilton Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Hamilton Health Sciences"},{"orgOrder":0,"company":"Tufts University","sponsor":"Prevention Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tufts University \/ Prevention Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tufts University \/ Prevention Pharmaceuticals"},{"orgOrder":0,"company":"University of Mississippi, Oxford","sponsor":"Walgreens","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"University of Mississippi, Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Mississippi, Oxford \/ Walgreens","highestDevelopmentStatusID":"1","companyTruncated":"University of Mississippi, Oxford \/ Walgreens"},{"orgOrder":0,"company":"d\u014dTERRA International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"d\u014dTERRA International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"d\u014dTERRA International \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"d\u014dTERRA International \/ Undisclosed"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Biodroga Inc. | University of Guelph","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Biodroga Inc. | University of Guelph","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Biodroga Inc. | University of Guelph"},{"orgOrder":0,"company":"Columbia University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ GSK"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Universidade Federal do Rio de Janeiro","sponsor":"Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Oncology","graph2":"Undisclosed","graph3":"Universidade Federal do Rio de Janeiro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universidade Federal do Rio de Janeiro \/ Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas","highestDevelopmentStatusID":"1","companyTruncated":"Universidade Federal do Rio de Janeiro \/ Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas"},{"orgOrder":0,"company":"GCP-Service International","sponsor":"University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"GCP-Service International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"GCP-Service International \/ University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp","highestDevelopmentStatusID":"8","companyTruncated":"GCP-Service International \/ University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp"}]

Find Clinical Drug Pipeline Developments & Deals for Fish Oil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 06, 2025

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Glogen Clinical Research Pvt. Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          dōTERRA International

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          dōTERRA International

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          GCP-Service International

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          GCP-Service International

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II

                          Sponsor : University Hospital, Bonn | University Hospital Muenster | University Hospital Göttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 28, 2024

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : University Hospital, Bonn | University Hospital Muenster | University Hospital Göttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Canadian College of Naturopathic Medicine

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Canadian College of Naturopathic Medicine

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Depression.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          October 10, 2023

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Sunnybrook Health Sciences Centre | Lotte & John Hecht Memorial Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Applied Science & Performance Institute

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Applied Science & Performance Institute

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          September 09, 2022

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : True Eye Experts - New Tampa

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Marinex International Sp. z o.o.

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Marinex International Sp. z o.o.

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 16, 2022

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Universidade Federal do Rio de Janeiro

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Universidade Federal do Rio de Janeiro

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 16, 2021

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Institutos Madrileño de Estudios Avanzados | Oncoclínicas

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University of Stirling

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          University of Stirling

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Aging.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 26, 2021

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Danone Nutricia Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Shanghai Mental Health Center

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Shanghai Mental Health Center

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Depressive Disorder, Major.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          April 02, 2019

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Yale University

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Yale University

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alcoholism.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 05, 2017

                          Lead Product(s) : Fish Oil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : VA Connecticut Healthcare System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank